Financial Statements

Regulus Therapeutics Inc. (RGLS)

$ 0.411
+0.02 (+4.85%)
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2020 2019 2018 2017 2016
Retained Earnings (Previous Year) -411-393-346-273-
Net Income -16-19-49-72-82
Stock Dividends --2-1-192
Dividend Paid -----
Retained Earnings -427-411-393-346-273

PPE Schedule

Year 2020 2019 2018 2017 2016
Gross PPE 181012-
Annual Depreciation -0-7-2-213
Capital Expenditure -0-0-0-0-1
Net PPE 0181012

Intangible and Goodwill Schedule

Year 2020 2019 2018 2017 2016
Intangible and Goodwill (Previous Year) -----
New Purchases -65-56---
Intangible and Goodwill -----

Regulus Therapeutics Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Regulus Therapeutics Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.